The bioavailability and maturing clearance of doxapram in preterm infants.

Robert B FlintSinno H P SimonsPeter AndriessenKian D LiemPieter L J DegraeuweIrwin K M ReissRob Ter HeineAline G J EngbersBirgit C P KochRonald de GrootDavid M BurgerCatherijne A J KnibbeSwantje Völlernull null

Published in: Pediatric research (2020)

Current dosing regimens of doxapram in preterm infants only based on bodyweight result in the highest exposure in infants with the lowest PNA and GA. Dosing of doxapram may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. Describing the pharmacokinetics of doxapram and its active metabolite keto-doxapram following intravenous and gastroenteral administration enables to include drug exposure to the evaluation of treatment of AOP. The oral bioavailability of doxapram in preterm neonates is 74%, requiring a 33% higher dose via oral than intravenous administration to maintain exposure.

Keyphrases

preterm infants
low birth weight
pet ct
high dose
preterm birth
emergency department
smoking cessation
adverse drug